{"ModuleTitle": "Company Description", "CompanyName": "Acorda Therapeutics, Inc.", "Symbol": "ACOR", "Address": "420 SAW MILL RIVER ROAD, ARDSLEY, New York, 10502, United States of America", "Phone": "914-347-4300", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on developing therapies that restore\r\nfunction and improve the lives of people with neurological disorders. We market\r\nInbrija (levodopa inhalation powder), which is approved in the U.S. for\r\nintermittent treatment of OFF episodes, also known as OFF periods, in people\r\nwith Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as\r\nneeded use and utilizes our ARCUS pulmonary delivery system, a technology\r\nplatform designed to deliver medication through inhalation that we believe has\r\npotential to be used in the development of a variety of inhaled medicines. We\r\nalso market branded Ampyra (dalfampridine) Extended Release Tablets, 10 mg.\r\n\r\nOur New Drug Application, or NDA, for Inbrija was approved by the U.S. Food and\r\nDrug Administration, or FDA, on December 21, 2018. The approval is for a single\r\ndose of 84 mg (administered as two capsules), which may be taken up to five\r\ntimes per day.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f28%2f0001564590-20-007789.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Andrew R. Blight", "title": "Chief Scientific Officer Emeritus"}, {"name": "Burkhard Blank", "title": "Chief Medical Officer, Head-R&D"}, {"name": "David Lawrence", "title": "Chief Accounting Officer"}, {"name": "Ronald Cohen", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}